Pharma-Bio Serv, Inc. (PBSV)
OTCMKTS · Delayed Price · Currency is USD
0.5400
+0.1175 (27.81%)
At close: Aug 20, 2026
Pharma-Bio Serv Ratios and Metrics
Market cap in millions USD. Fiscal year is November - October.
Millions USD. Fiscal year is Nov - Oct.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
| 12 | 12 | 13 | 20 | 20 | 24 | |
Market Cap Growth | -10.10% | -7.06% | -31.76% | -1.11% | -16.81% | -20.06% |
Enterprise Value | 4 | 2 | 1 | 5 | 6 | 8 |
Last Close Price | 0.54 | 0.47 | 0.44 | 0.60 | 0.57 | 0.58 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
PE Ratio | 201.34 | - | - | 14.89 | 19.60 | - |
Forward PE | 5.40 | 4.91 | 5.27 | 7.73 | 13.23 | 12.12 |
PS Ratio | 1.36 | 1.38 | 1.40 | 1.15 | 1.02 | 1.18 |
PB Ratio | 1.18 | 1.04 | 0.97 | 1.21 | 1.19 | 1.25 |
P/TBV Ratio | 1.18 | 1.04 | 0.97 | 1.21 | 1.19 | 1.25 |
P/FCF Ratio | - | - | - | 10.36 | 34.42 | 29.87 |
P/OCF Ratio | - | - | - | 10.32 | 33.31 | 29.47 |
PEG Ratio | - | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
EV/Sales Ratio | 0.43 | 0.19 | 0.07 | 0.31 | 0.31 | 0.39 |
EV/EBITDA Ratio | - | - | - | 4.56 | 4.91 | - |
EV/EBIT Ratio | - | - | - | 4.75 | 5.12 | - |
EV/FCF Ratio | - | - | - | 2.82 | 10.49 | 9.97 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Debt / Equity Ratio | - | 0.00 | 0.01 | 0.02 | 0.03 | 0.03 |
Debt / EBITDA Ratio | - | - | - | 0.26 | 0.35 | - |
Debt / FCF Ratio | - | - | - | 0.18 | 0.85 | 0.78 |
Net Debt / Equity Ratio | -0.81 | -0.91 | -0.91 | -0.91 | -0.84 | -0.89 |
Net Debt / EBITDA Ratio | 25.14 | 18.74 | 9.93 | -12.55 | -11.40 | 4.46 |
Net Debt / FCF Ratio | 34.39 | 48.87 | 17.28 | -7.77 | -24.38 | -21.22 |
Asset Turnover | 0.72 | 0.60 | 0.53 | 0.84 | 0.87 | 0.75 |
Quick Ratio | 10.71 | 7.60 | 8.08 | 8.78 | 9.23 | 8.27 |
Current Ratio | 10.80 | 7.70 | 8.32 | 9.01 | 9.46 | 8.55 |
Return on Equity (ROE) | 0.55% | -0.78% | -5.21% | 8.02% | 5.68% | -10.04% |
Return on Assets (ROA) | -1.95% | -2.66% | -4.45% | 3.44% | 3.29% | -8.95% |
Return on Invested Capital (ROIC) | -41.38% | -56.62% | -96.81% | 42.55% | 42.85% | -74.35% |
Return on Capital Employed (ROCE) | -3.80% | -5.40% | -8.90% | 6.30% | 6.30% | -18.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Earnings Yield | 0.50% | -0.81% | -5.84% | 6.71% | 5.10% | -8.81% |
FCF Yield | -1.99% | -1.79% | -5.46% | 9.65% | 2.90% | 3.35% |
Payout Ratio | 2793.16% | - | - | 131.57% | 342.37% | - |
Buyback Yield / Dilution | 0.09% | 0.07% | 0.10% | 0.15% | 0.56% | -0.53% |